Journal of Clinical Epidemiology
Volume 58, Issue 8 , Pages 757-762 , August 2005

Both clinical epidemiology and population health perspectives can define the role of health care in reducing health disparities

  • Geoffrey M. Anderson

      Affiliations

    • Department of Health Policy, Management and Evaluation, Faculty of Medicine, University of Toronto, McMurrich Building, 2nd floor, 12 Queen's Park Crescent West, Toronto, Ontario M5S 1A8, Canada
    • Institute for Clinical Evaluative Sciences, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada
    • Corresponding Author InformationCorresponding author. Tel.: 416-946-3770; fax: 416-978-7350.
    • ,
  • Susan E. Bronskill

      Affiliations

    • Department of Health Policy, Management and Evaluation, Faculty of Medicine, University of Toronto, McMurrich Building, 2nd floor, 12 Queen's Park Crescent West, Toronto, Ontario M5S 1A8, Canada
    • Institute for Clinical Evaluative Sciences, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada
    • ,
  • Cameron A. Mustard

      Affiliations

    • Department of Public Health Sciences, University of Toronto, Toronto, Ontario M5S 1A8, Canada
    • Institute for Work & Health, 481 University Avenue, Suite 800, Toronto, Ontario M5G 2E9, Canada
    • ,
  • Anthony Culyer

      Affiliations

    • Institute for Work & Health, 481 University Avenue, Suite 800, Toronto, Ontario M5G 2E9, Canada
    • ,
  • David A. Alter

      Affiliations

    • Institute for Clinical Evaluative Sciences, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada
    • Schulich Heart Centre, Sunnybrook & Women's College Health Sciences Centre, Toronto, Ontario M4N 3M5, Canada
    • Department of Medicine, University of Toronto, Toronto, Ontario M5G 2C4, Canada
    • ,
  • Douglas G. Manuel

      Affiliations

    • Institute for Clinical Evaluative Sciences, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada
    • Department of Public Health Sciences, University of Toronto, Toronto, Ontario M5S 1A8, Canada

,Accepted 29 October 2004.

References 

  1. Frank JW, Mustard JF. The determinants of health from a historical perspective. Daedalus. 1994;123:1–19
  2. Marmot MG, Smith GD, Stansfeld S, Patel C, North F, Head J, et al. Health inequalities among British civil servants: the Whitehall II study. Lancet. 1991;337:1387–1393
  3. Marmot M. The influence of income on health: views of an epidemiologist. Does money really matter? Or is it a marker for something else?. Health Aff (Millwood). 2002;21:31–46
  4. Deaton A. Policy implications of the gradient of health and wealth. An economist asks, would redistributing income improve population health?. Health Aff (Millwood). 2002;21:13–30
  5. Tarlov AR. Public policy frameworks for improving population health. Ann NY Acad Sci. 1999;896:281–293
  6. Evans RG, Stoddart GL. Producing health, consuming health care. In:  Evans RG,  Barer ML,  Marmor TR editor. Why are some people healthy and others not? The determinants of health of populations. New York: Aldine de Gruyter; 1994;p. 27–64
  7. Cassel J. The contribution of the social environment to host resistance: the Fourth Wade Hampton Frost Lecture. 1976. Am J Epidemiol. 1995;141:798–814discussion, 797
  8. Kaplan JR, Adams MR, Clarkson TB, Manuck SB, Shively CA, Williams JK. Psychosocial factors, sex differences, and atherosclerosis: lessons from animal models. Psychosom Med. 1996;58:598–611
  9. Lantz PM, House JS, Lepkowski JM, Williams DR, Mero RP, Chen J. Socioeconomic factors, health behaviors, and mortality: results from a nationally representative prospective study of US adults. JAMA. 1998;279:1703–1708
  10. Chin NP, Monroe A, Fiscella K. Social determinants of (un)healthy behaviors. Educ Health (Abingdon). 2000;13:317–328
  11. Lavis JN, Stoddart GL. Can we have too much health care?. Daedalus. 1994;123:43–60
  12. Evans RG. Health care as a threat to health: defense, opulence, and the social environment. Daedalus. 1994;123:21–42
  13. Fletcher RH, Fletcher SW, Wagner EH. Clinical epidemiology: the essentials. ed 3.. Baltimore, MD: Williams & Wilkins; 1998;
  14. Guyatt GH, Sackett DL, Cook DJ. Evidence-Based Medicine Working Group. Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid?. JAMA. 1993;270:2598–2601
  15. Furukawa TA, Guyatt GH, Griffith LE. Can we individualize the ‘number needed to treat’? An empirical study of summary effect measures in meta-analyses. Int J Epidemiol. 2002;31:72–76
  16. McAlister FA. Commentary: Relative treatment effects are consistent across the spectrum of underlying risks … usually. Int J Epidemiol. 2002;31:76–77
  17. Hypertension Detection and Follow-up Program Cooperative Group . Educational level and 5-year all-cause mortality in the Hypertension Detection and Follow-up Program. Hypertension. 1987;9:641–646
  18. Scandinavian Simvastatin Survival Study (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  19. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009
  20. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group . Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–1357
  21. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615–1622
  22. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301–1307
  23. Tugwell P, Bennett K, Feeny D, Guyatt G, Haynes RB. A framework for the evaluation of technology: the technology assessment iterative loop. In:  Feeny D,  Guyatt G,  Tugwell P editor. Health care technology: effectiveness, efficiency, and public policy. Montreal: Institute for Research on Public Policy; 1986;p. 41–56
  24. Alter DA, Naylor CD, Austin P, Tu JV. Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction. N Engl J Med. 1999;34:1359–1367
  25. Kapral MK, Wang H, Mamdani M, Tu J. Effect of socioeconomic status on treatment and mortality after stroke. Stroke. 2002;33:268–273
  26. Fiscella K, Franks P, Gold MR, Clancy CM. Inequality in quality: addressing socioeconomic, racial, and ethnic disparities in health care. JAMA. 2000;283:2579–2584
  27. Burstin HR, Lipsitz SR, Brennan TA. Socioeconomic status and risk for substandard medical care. JAMA. 1992;268:2383–2387
  28. O'Brien BJ, Heyland D, Richardson S, Levine M, Drummond MF. Users' guides to the medical literature. XIII. How to use an article on economic analysis. B. What are the results and will they help me in caring for my patients?. JAMA. 1997;277:1802–1806[Erratum in: JAMA 1997;278:1064]
  29. Graham JD, Corso PS, Morris JM, Segui-Gomez M, Weinstein MC. Evaluating the cost-effectiveness of clinical and public health measures. Annu Rev Public Health. 1998;19:125–152

PII: S0895-4356(05)00049-1

doi: 10.1016/j.jclinepi.2004.10.020

Journal of Clinical Epidemiology
Volume 58, Issue 8 , Pages 757-762 , August 2005

Article Tools

* Image Usage & Resolution